Organ-Specific Differences in Immunotherapy Response Among Metastatic Cancer Patients
Real-world Evidence and Multi-omics Insights Into Differential Immunotherapy Responses Between Primary and Metastatic Sites
This study examines how tumors in different metastatic organs respond to immune checkpoint inhibitor (ICB) therapy in real-world clinical practice. ICB therapy helps the immune system recognize and attack cancer cells, but treatment responses may vary depending on where the cancer has spread. Common metastatic sites such as the liver, brain, lung, and bone each have unique immune environments that may influence treatment outcomes.
The investigators will review the medical records of approximately 1,000 adults with solid tumors who received ICB therapy at Sun Yat-sen Memorial Hospital, the Third Affiliated Hospital of Sun Yat-sen University, and the First Affiliated Hospital of Chongqing Medical University since 2016. The study will compare treatment response, time until disease progression, and overall survival among patients with different metastatic sites. Additional outcomes include disease control, immunotherapy-related side effects, and concordance between primary and metastatic tumor responses.
The study will also analyze available molecular and immune-profiling datasets to explore biological mechanisms that may explain organ-specific differences in ICB response. The goal is to improve understanding of how metastatic sites influence immunotherapy effectiveness and to support future treatment decision-making.
Studie Overzicht
Toestand
Studietype
Inschrijving (Werkelijk)
Contacten en locaties
Studie Locaties
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Bemonsteringsmethode
Studie Bevolking
Beschrijving
Inclusion Criteria:
- Age ≥18 years.
- Pathologically confirmed solid tumor with a documented primary tumor site.
- At least one metastatic site in the brain, liver, lung, or bone confirmed by imaging or pathology (single or multiple lesions allowed).
- Received first-line or second-line immune checkpoint inhibitor (ICB) therapy, including PD-1, PD-L1, or CTLA-4 inhibitors, either alone or in combination.
- Completed at least 3 cycles of ICB therapy.
- At least one evaluable imaging follow-up after initiation of immunotherapy.
- Available clinical and follow-up data, including treatment initiation date, response assessment, progression status, and survival status.
- Meets institutional ethics requirements for retrospective studies.
Exclusion Criteria:
- Unclear or undocumented metastatic site, or lack of imaging/pathologic evidence supporting metastasis.
- ICB treatment regimen cannot be clearly determined (e.g., unclear combination therapy components).
- Missing more than 20% of key clinical variables or incomplete follow-up data (e.g., missing PFS or OS information).
- Received fewer than 3 cycles of ICB therapy.
- Major treatment interruption or poor treatment adherence.
- Concurrent active malignancy that may interfere with outcome assessment.
- Severe immune-related disease (e.g., systemic lupus erythematosus) or organ transplantation requiring long-term immunosuppression.
- Participation in another interventional clinical trial that may affect treatment evaluation.
- Data errors or logical inconsistencies that cannot be resolved after review.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
Cohorten en interventies
Groep / Cohort |
|---|
|
Metastatic cancers treated with immune checkpoint inhibitors
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Organ-Specific Objective Response Rate (osORR)
Tijdsspanne: At first radiographic assessment after immunotherapy initiation (approximately 6-12 weeks).
|
osORR is the percentage of patients whose tumors in a specific metastatic organ (brain, liver, lung, or bone) achieve a complete response (CR) or partial response (PR) following immunotherapy, as assessed according to RECIST v1.1.
Each metastatic organ is evaluated separately.
|
At first radiographic assessment after immunotherapy initiation (approximately 6-12 weeks).
|
|
Organ-Specific Progression-Free Survival (osPFS)
Tijdsspanne: Up to 5 years.
|
osPFS is defined as the time from initiation of immunotherapy to disease progression within the specific metastatic organ or death from any cause, whichever occurs first.
Progression is assessed according to RECIST v1.1 based on target lesions within the corresponding organ, regardless of progression occurring in other organs.
|
Up to 5 years.
|
|
Overall Survival (OS)
Tijdsspanne: From start of ICB treatment until death from any cause (up to 5 years).
|
In this retrospective study, OS is defined as the time from initiation of immune checkpoint blockade (ICB) therapy to death from any cause.
Survival time is determined using available longitudinal follow-up records.
Patients who are alive at the last follow-up will be censored.
|
From start of ICB treatment until death from any cause (up to 5 years).
|
Medewerkers en onderzoekers
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- SYSKY-2025-902-01
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .